GALT Earnings Date: Nov 13, 2026 (Estimated) — Galectin Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is GALT's next earnings date?
Galectin Therapeutics Inc. (GALT) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.05.
How did GALT do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Galectin Therapeutics Inc. posted EPS of -$0.14 versus the -$0.09 estimate, a miss of 55.6%. Revenue was $0. The stock's 1-day post-earnings move was -2.5%.
How much does GALT stock move after earnings?
GALT beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.2% (up or down) in the day after earnings.
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.09 | -0.14 | -55.56% | $0 | ❌ Miss | -2.55% | +1.13% | +8.78% |
| 2026-05-15 | Q1 2026 | -0.06 | -0.08 | -33.33% | $0 | ❌ Miss | -7.66% | +7.23% | +11.49% |
| 2026-03-31 | Q4 2025 | -0.10 | -0.08 | +20.00% | $0 | ✅ Beat | +8.56% | -14.79% | -12.45% |
| 2025-11-14 | Q3 2025 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | -0.36% | +3.80% | +17.72% |
| 2025-08-14 | Q2 2025 | -0.16 | -0.12 | +25.00% | $0 | ✅ Beat | +2.45% | +6.27% | +46.32% |
| 2025-03-31 | Q4 2024 | -0.21 | -0.19 | +9.52% | $0 | ✅ Beat | -19.74% | -13.16% | -17.76% |
| 2024-11-13 | Q3 2024 | -0.20 | -0.18 | +10.00% | $0 | ✅ Beat | -2.03% | -6.93% | -32.77% |
| 2024-08-13 | Q2 2024 | -0.16 | -0.20 | -25.00% | $0 | ❌ Miss | +6.64% | +11.37% | +29.86% |
Showing last 8 quarters.